Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles P Hart

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Molecular Cancer Therapeutics|July 9, 2013
Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitroJinsong Hu, Els Van Valckenborgh, Dehui Xu, et al.
Neuro-Oncology|February 8, 2018
Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical studyAndrew Brenner, Richard Zuniga, Jessica D Sun, et al.
Journal of Medicinal Chemistry|February 24, 2011
14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatmentJian-Xin Duan, Xiaohong Cai, Fanying Meng, et al.
Cancer Chemotherapy and Pharmacology|March 3, 2012
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedulesQian Liu, Jessica D Sun, Jingli Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2016
Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver CancerRafael Duran, Sahar Mirpour, Vasily Pekurovsky, et al.
Plos One|September 26, 2014
Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302Yoichi Takakusagi, Shingo Matsumoto, Keita Saito, et al.
Journal of Medicinal Chemistry|February 9, 2008
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugsJian-Xin Duan, Hailong Jiao, Jacob Kaizerman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2015
TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET ImagingSarah G J A Peeters, Catharina M L Zegers, Rianne Biemans, et al.
Molecular Cancer Therapeutics|December 8, 2011
Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302Fanying Meng, James W Evans, Deepthi Bhupathi, et al.
Blood|March 8, 2012
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like featuresAbdel Kareem Azab, Jinsong Hu, Phong Quang, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Molecular Cancer Therapeutics|July 9, 2013
Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitroJinsong Hu, Els Van Valckenborgh, Dehui Xu, et al.
Neuro-Oncology|February 8, 2018
Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical studyAndrew Brenner, Richard Zuniga, Jessica D Sun, et al.
Journal of Medicinal Chemistry|February 24, 2011
14-Aminocamptothecins: their synthesis, preclinical activity, and potential use for cancer treatmentJian-Xin Duan, Xiaohong Cai, Fanying Meng, et al.
Cancer Chemotherapy and Pharmacology|March 3, 2012
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedulesQian Liu, Jessica D Sun, Jingli Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2016
Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver CancerRafael Duran, Sahar Mirpour, Vasily Pekurovsky, et al.
Plos One|September 26, 2014
Pyruvate induces transient tumor hypoxia by enhancing mitochondrial oxygen consumption and potentiates the anti-tumor effect of a hypoxia-activated prodrug TH-302Yoichi Takakusagi, Shingo Matsumoto, Keita Saito, et al.
Journal of Medicinal Chemistry|February 9, 2008
Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugsJian-Xin Duan, Hailong Jiao, Jacob Kaizerman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2015
TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET ImagingSarah G J A Peeters, Catharina M L Zegers, Rianne Biemans, et al.
Molecular Cancer Therapeutics|December 8, 2011
Molecular and cellular pharmacology of the hypoxia-activated prodrug TH-302Fanying Meng, James W Evans, Deepthi Bhupathi, et al.
Blood|March 8, 2012
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like featuresAbdel Kareem Azab, Jinsong Hu, Phong Quang, et al.
Pageof 4